Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] SK Square (402340) – Decision on Stock Retirement / 2026-07-22

Posted on July 22, 2026July 30, 2026 By K-STOCK Editor No Comments on [Disclosure] SK Square (402340) – Decision on Stock Retirement / 2026-07-22

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

SK Square resolved to retire 34,388 shares of previously acquired common treasury stock (estimated retirement value of approx. KRW 43.09B) on July 31, 2026.

📊 [Summary of Key Disclosure Facts & Figures]

1. Stock Retirement Details

  • Type & Number of Shares to be Retired: Common Stock 34,388 shares
  • Total Number of Issued Shares: Common Stock 131,958,386 shares
  • Par Value per Share: KRW 100
  • Scheduled Retirement Value: KRW 43,088,164,000 (approx. KRW 43.09B, based on the closing price preceding the board resolution date)

2. Retirement Method & Schedule

  • Acquisition Method of Retired Shares: Previously acquired treasury stock (acquisition completed following board resolution on March 25, 2026)
  • Scheduled Retirement Date: 2026-07-31
  • Board Resolution Date: 2026-07-22 (5 Independent Directors attended)

3. Other Key Investment Notes

  • As treasury stock acquired within dividendable profits is being retired, the total number of issued shares will decrease without any reduction in capital stock.
  • This disclosure replaces the announcement for disposition of treasury stock.
  • The scheduled retirement date may be subject to change depending on consultations with relevant institutions.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Stock Retirement Completion and Subsequent Filings

This disclosure notifies the decision to retire previously acquired treasury shares. As the retirement is conducted within dividendable profits by board resolution, the total number of issued shares will decrease without reducing capital stock. Reviewing whether the retirement procedure is completed according to the scheduled date (2026-07-31) and confirming the updated share count through subsequent official disclosures, such as listing modification announcements, is relevant.

📢 Disclaimer & Source Information

Source: This content was newly structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] SK Square (402340) – New Facility Investment / 2026-07-22
Next Post: [Disclosure] Samsung Biologics (207940) – Consolidated Financial Results (Preliminary) / 2026-07-23

Related Posts

[Disclosure] Celltrion (068270) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-12-11 Disclosures
[Disclosure] Wonik IPS (240810) – Decision on Calling of General Shareholders’ Meeting / 2026-02-25 Semiconductors
[Disclosure] ALTEOGEN (196170) – Resolution on Convocation of General Meeting of Shareholders / 2026-03-16 Disclosures
[Disclosure] Jusung Engineering (036930) – Investor Relations (IR) Presentation / 2025-08-25 Semiconductors
[Disclosure] Jusung Engineering(036930) – (Correction) Split Decision (Physical Split) / 2024-07-04 Semiconductors
[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract (Voluntary Disclosure) / 2025-08-26 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme